IL276817A - 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer - Google Patents
7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancerInfo
- Publication number
- IL276817A IL276817A IL276817A IL27681720A IL276817A IL 276817 A IL276817 A IL 276817A IL 276817 A IL276817 A IL 276817A IL 27681720 A IL27681720 A IL 27681720A IL 276817 A IL276817 A IL 276817A
- Authority
- IL
- Israel
- Prior art keywords
- prophylaxis
- derivatives
- treatment
- liver cancer
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018077501 | 2018-02-28 | ||
| PCT/EP2019/054729 WO2019166432A1 (en) | 2018-02-28 | 2019-02-26 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL276817A true IL276817A (en) | 2020-10-29 |
Family
ID=65685310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276817A IL276817A (en) | 2018-02-28 | 2020-08-19 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3758707A1 (en) |
| JP (1) | JP7089596B2 (en) |
| KR (1) | KR20200128414A (en) |
| CN (1) | CN111801100B (en) |
| AR (1) | AR114419A1 (en) |
| AU (1) | AU2019228654A1 (en) |
| BR (1) | BR112020016509A2 (en) |
| CA (1) | CA3091950A1 (en) |
| CL (1) | CL2020002139A1 (en) |
| CO (1) | CO2020010306A2 (en) |
| IL (1) | IL276817A (en) |
| MA (1) | MA52412A (en) |
| MX (1) | MX2020008746A (en) |
| PE (1) | PE20211456A1 (en) |
| PH (1) | PH12020551343A1 (en) |
| RU (1) | RU2020131012A (en) |
| SG (1) | SG11202008291XA (en) |
| TW (1) | TW202003518A (en) |
| WO (1) | WO2019166432A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170169A1 (en) | 2016-08-29 | 2019-01-30 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
| KR102409595B1 (en) | 2020-06-29 | 2022-06-17 | 한국과학기술연구원 | Novel purinone derivatives as protein kinase CSF-1R inhibitor |
| CN112420196A (en) * | 2020-11-20 | 2021-02-26 | 长沙市弘源心血管健康研究院 | Prediction method and system for survival rate of acute myocardial infarction patient within 5 years |
| WO2024013205A1 (en) * | 2022-07-14 | 2024-01-18 | F. Hoffmann-La Roche Ag | Phosphorylpurinone compounds for the treatment of cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (en) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | Heterocyclic compounds |
| EP2364314B1 (en) | 2008-12-09 | 2014-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| BRPI1010937A2 (en) * | 2009-05-21 | 2019-09-24 | Astrazeneca Ab | compound, use of a compound, and method for treating cancer |
| JP5694345B2 (en) * | 2009-10-22 | 2015-04-01 | ギリアード サイエンシーズ， インコーポレイテッド | Regulators of TOLL-like receptors |
| WO2011079016A1 (en) * | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| AU2011270701B2 (en) | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| WO2012021834A1 (en) * | 2010-08-13 | 2012-02-16 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| KR20180003612A (en) | 2015-05-08 | 2018-01-09 | 에프. 호프만-라 로슈 아게 | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prevention of viral infections |
| MA44334A (en) | 2015-10-29 | 2018-09-05 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST |
| PT3504210T (en) * | 2016-08-29 | 2021-04-19 | H Hoffnabb La Roche Ag | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
| KR102497701B1 (en) * | 2016-09-13 | 2023-02-09 | 에프. 호프만-라 로슈 아게 | Combination therapy of a TLR7 agonist and an HBV capsid assembly inhibitor |
-
2019
- 2019-02-26 AU AU2019228654A patent/AU2019228654A1/en not_active Abandoned
- 2019-02-26 CA CA3091950A patent/CA3091950A1/en active Pending
- 2019-02-26 EP EP19708981.6A patent/EP3758707A1/en active Pending
- 2019-02-26 KR KR1020207027935A patent/KR20200128414A/en unknown
- 2019-02-26 MA MA052412A patent/MA52412A/en unknown
- 2019-02-26 WO PCT/EP2019/054729 patent/WO2019166432A1/en unknown
- 2019-02-26 CN CN201980015912.7A patent/CN111801100B/en active Active
- 2019-02-26 MX MX2020008746A patent/MX2020008746A/en unknown
- 2019-02-26 JP JP2020544794A patent/JP7089596B2/en active Active
- 2019-02-26 RU RU2020131012A patent/RU2020131012A/en unknown
- 2019-02-26 BR BR112020016509-3A patent/BR112020016509A2/en not_active Application Discontinuation
- 2019-02-26 SG SG11202008291XA patent/SG11202008291XA/en unknown
- 2019-02-26 PE PE2020001228A patent/PE20211456A1/en unknown
- 2019-02-27 TW TW108106752A patent/TW202003518A/en unknown
- 2019-02-28 AR ARP190100505A patent/AR114419A1/en unknown
-
2020
- 2020-08-19 CL CL2020002139A patent/CL2020002139A1/en unknown
- 2020-08-19 IL IL276817A patent/IL276817A/en unknown
- 2020-08-21 CO CONC2020/0010306A patent/CO2020010306A2/en unknown
- 2020-08-27 PH PH12020551343A patent/PH12020551343A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020131012A (en) | 2022-03-28 |
| CN111801100B (en) | 2023-10-24 |
| CO2020010306A2 (en) | 2020-08-31 |
| AR114419A1 (en) | 2020-09-02 |
| KR20200128414A (en) | 2020-11-12 |
| TW202003518A (en) | 2020-01-16 |
| CN111801100A (en) | 2020-10-20 |
| MX2020008746A (en) | 2020-09-28 |
| EP3758707A1 (en) | 2021-01-06 |
| WO2019166432A1 (en) | 2019-09-06 |
| CL2020002139A1 (en) | 2021-01-04 |
| JP7089596B2 (en) | 2022-06-22 |
| PH12020551343A1 (en) | 2021-06-21 |
| JP2021514972A (en) | 2021-06-17 |
| CA3091950A1 (en) | 2019-09-06 |
| AU2019228654A1 (en) | 2020-09-03 |
| PE20211456A1 (en) | 2021-08-05 |
| BR112020016509A2 (en) | 2020-12-15 |
| SG11202008291XA (en) | 2020-09-29 |
| MA52412A (en) | 2021-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3781564C0 (en) | Pyridazine derivatives for the treatment of cancer | |
| EP3894392A4 (en) | Compositions and methods for the treatment of cancer | |
| EP4010080C0 (en) | Heterocyclic compounds for use in the treatment of cancer | |
| IL276817A (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
| ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
| IL279347A (en) | Gremlin-1 antagonist for the prevention and treatment of cancer | |
| IL263793A (en) | Compounds and compositions for the treatment of cancer | |
| IL268676A (en) | Inhibition of smarca2 for treatment of cancer | |
| IL280587B (en) | Flurocytidine derivatives and its composition for the treatment of cancer | |
| SG11202108636SA (en) | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | |
| IL283885A (en) | Cxcr7 inhibitors for the treatment of cancer | |
| IL272147A (en) | Methods and compositions for the treatment of cancer | |
| EP3681498A4 (en) | Methods and compositions for the treatment of cancer | |
| IL286649A (en) | Quinoline derivatives and their use for the treatment of cancer | |
| IL282313A (en) | Abituzumab for the treatment of colorectal cancer | |
| IL280262A (en) | Compositions and methods for the treatment of cancer | |
| IL284124A (en) | Quinoline derivatives for use in the treatment or prevention of cancer | |
| EP3987032A4 (en) | Methods and compositions for the treatment of cancer | |
| ZA202005311B (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
| EP3846797A4 (en) | Use of delta-tocotrienol for treating cancer | |
| EP3630754B8 (en) | Isoindoline-acetylene compounds for the treatment of cancer | |
| EP3538102A4 (en) | Inhibition of kmt2d for the treatment of cancer | |
| EP3440134A4 (en) | Lls compounds for treatment of cancer | |
| AU2018900827A0 (en) | Methods and compounds for the treatment of cancer | |
| AU2018904604A0 (en) | Methods and compositions for the treatment of cancer |